MX2008001865A - Albumin fusion proteins. - Google Patents

Albumin fusion proteins.

Info

Publication number
MX2008001865A
MX2008001865A MX2008001865A MX2008001865A MX2008001865A MX 2008001865 A MX2008001865 A MX 2008001865A MX 2008001865 A MX2008001865 A MX 2008001865A MX 2008001865 A MX2008001865 A MX 2008001865A MX 2008001865 A MX2008001865 A MX 2008001865A
Authority
MX
Mexico
Prior art keywords
fusion proteins
albumin fusion
nucleic acids
vectors
host cells
Prior art date
Application number
MX2008001865A
Other languages
Spanish (es)
Inventor
Adam Bell
Yanggu Shi
David Lafleur
Craig Rosen
Paul Moore
Michael Laird
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of MX2008001865A publication Critical patent/MX2008001865A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
MX2008001865A 2005-08-12 2006-07-31 Albumin fusion proteins. MX2008001865A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15
PCT/US2006/029391 WO2007021494A2 (en) 2005-08-12 2006-07-31 Albumin fusion proteins

Publications (1)

Publication Number Publication Date
MX2008001865A true MX2008001865A (en) 2008-04-15

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001865A MX2008001865A (en) 2005-08-12 2006-07-31 Albumin fusion proteins.

Country Status (13)

Country Link
EP (1) EP1924596A4 (en)
JP (1) JP2009504157A (en)
KR (1) KR20080071119A (en)
AU (1) AU2006280312A1 (en)
BR (1) BRPI0614761A2 (en)
CA (1) CA2618476A1 (en)
EC (1) ECSP088262A (en)
IL (1) IL189246A0 (en)
MA (1) MA29836B1 (en)
MX (1) MX2008001865A (en)
NO (1) NO20081233L (en)
TN (1) TNSN08064A1 (en)
WO (1) WO2007021494A2 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
JP2003530839A (en) 2000-04-12 2003-10-21 プリンシピア ファーマスーティカル コーポレイション Albumin fusion protein
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
SI1729795T1 (en) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albumin fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
BRPI0712383A2 (en) 2006-06-07 2012-07-10 Human Genome Sciences Inc albumin fusion proteins
US20100254944A1 (en) * 2006-09-14 2010-10-07 Mani Subramanian Albumin Fusion Proteins
CN103755789B (en) 2007-01-30 2016-12-07 埃皮瓦克斯公司 Regulatory t cell epitopes, compositions and application thereof
BRPI0915093A2 (en) 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugates for the administration of biologically active compounds
CN102378635A (en) 2009-01-16 2012-03-14 特瓦制药工业有限公司 Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
KR20100100254A (en) * 2009-03-05 2010-09-15 (주)바이오큐어팜 Composition for preventing or treating cancer comprising human serum albumin-timp-2 fusion protein and anti-cancer agent
EP2470670A4 (en) 2009-08-24 2013-07-10 Amunix Operating Inc Coagulation factor vii compositions and methods of making and using same
MX2012004793A (en) * 2009-10-30 2012-07-20 Novozymes Biopharma Dk As Albumin variants.
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
AU2011255238B2 (en) * 2010-05-21 2015-06-04 Silver Creek Pharmaceuticals, Inc. Bi-specific fusion proteins
CN103402542B (en) * 2011-02-28 2017-05-03 独立行政法人国立循环器病研究中心 Medicinal agent for inhibiting metastasis of malignant tumor
US8822417B2 (en) 2011-05-05 2014-09-02 Novozymes Biopharma DIC A/S Albumin variants
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
PT2717898T (en) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Pro-coagulant compounds and methods of use thereof
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (en) 2011-10-21 2015-03-19 Abbvie Inc. Method for the treatment of HCV comprising at least two direct-acting antiviral agents, ribavirin but not interferon
DE202012013117U1 (en) 2011-10-21 2015-01-16 Abbvie Inc. Combination treatment (e.g., with ABT-072 or ABT-333 from DAAs for use in the treatment of HCV)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
EP2804623B1 (en) 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
HUE046848T2 (en) 2012-02-15 2020-03-30 Bioverativ Therapeutics Inc Factor viii compositions and methods of making and using same
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
BR112014018679A2 (en) 2012-03-16 2017-07-04 Novozymes Biopharma Dk As albumin variants
CN104519897A (en) 2012-06-08 2015-04-15 比奥根艾迪克Ma公司 Procoagulant compounds
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
CN103525695B (en) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 Portable kidney function detecting system
SG10201701037WA (en) 2012-07-11 2017-03-30 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
RS64664B1 (en) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc Optimized factor viii gene
EP3318124A3 (en) 2013-02-16 2018-05-30 Albumedix A/S Pharmacokinetic animal model
TWI745671B (en) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 Factor ix polypeptide formulations
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
HUE059820T2 (en) 2014-01-10 2022-12-28 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
KR102122463B1 (en) 2014-10-14 2020-06-15 할로자임, 아이엔씨 Compositions of Adenosine Deaminase-2 (ADA2), Variants thereof and Methods of Using Same
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
JP6909203B2 (en) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド Factor IX fusion proteins and their production and usage
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
WO2017059231A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
CN105254766B (en) * 2015-10-26 2018-10-16 中国航天员科研训练中心 Application of the Mecano growth factor MGF E domain peptides in regulation and control memory related gene and miRNA expression
JP7217630B2 (en) 2016-02-01 2023-02-03 バイオベラティブ セラピューティクス インコーポレイテッド Optimized Factor VIII gene
CN109689063A (en) 2016-04-28 2019-04-26 埃默里大学 Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses
CN110337590A (en) 2016-11-04 2019-10-15 奥胡斯大学 The identification and treatment of tumour characterized by neonatal Fc receptor is overexpressed
JP2020500874A (en) 2016-12-02 2020-01-16 バイオベラティブ セラピューティクス インコーポレイテッド Method of treating hemophilic arthropathy using chimeric clotting factor
MX2019006446A (en) 2016-12-02 2019-12-11 Bioverativ Therapeutics Inc Methods of inducing immune tolerance to clotting factors.
US20200031895A1 (en) 2016-12-16 2020-01-30 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
CA3051862A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
US20200131225A1 (en) * 2017-04-20 2020-04-30 Novo Nordisk A/S Methods of purification of albumin fusion proteins
WO2019032898A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
EP3746136A1 (en) 2018-02-01 2020-12-09 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
CN113227385A (en) 2018-08-09 2021-08-06 比奥维拉迪维治疗股份有限公司 Nucleic acid molecules and their use for non-viral gene therapy
US20200199626A1 (en) 2018-12-06 2020-06-25 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
CA3152600A1 (en) 2019-09-30 2021-04-08 Andrew KROETSCH Lentiviral vector formulations
JPWO2022030580A1 (en) * 2020-08-06 2022-02-10

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261250B1 (en) * 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2005003296A2 (en) * 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
SI1729795T1 (en) * 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albumin fusion proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
ECSP088262A (en) 2008-05-30
BRPI0614761A2 (en) 2009-05-19
CA2618476A1 (en) 2007-02-22
WO2007021494A2 (en) 2007-02-22
MA29836B1 (en) 2008-10-03
WO2007021494A3 (en) 2007-07-26
EP1924596A4 (en) 2009-07-29
AU2006280312A1 (en) 2007-02-22
IL189246A0 (en) 2008-08-07
EP1924596A2 (en) 2008-05-28
JP2009504157A (en) 2009-02-05
KR20080071119A (en) 2008-08-01
TNSN08064A1 (en) 2009-07-14
NO20081233L (en) 2008-05-09

Similar Documents

Publication Publication Date Title
TNSN08064A1 (en) Albumin fusion proteins
MX2009002816A (en) Albumin fusion proteins.
WO2007146038A3 (en) Albumin fusion proteins
WO2005077042A3 (en) Albumin fusion proteins
WO2005003296A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
WO2001079443A3 (en) Albumin fusion proteins
WO2003030821A3 (en) Albumin fusion proteins
AU2017263237A1 (en) GDF15 fusion proteins and uses thereof
ES2353814T3 (en) RECOMBINANT N-GLYCOSILATED PROTEINS OF PROCEDURAL CELLS.
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EA201270758A1 (en) FGF21 MUTANTS AND THEIR APPLICATIONS
EA201171220A1 (en) FGF21 MUTANTS AND THEIR APPLICATIONS
IN2012DN02981A (en)
MX2009004243A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use.
WO2006017355A3 (en) Improved aprotinin variants
TW200724679A (en) Treatment of disease using an improved regulated expression system
WO2002097110A3 (en) TUMOR ENDOTHELIAL MARKER 7α MOLECULES AND USES THEREOF
WO2006110367A3 (en) Methods and compositions for mycoplasma toxins

Legal Events

Date Code Title Description
FA Abandonment or withdrawal